Phibro Animal Health Corporation entered into an amended and restated credit agreement. Under the amended and restated credit agreement, the lenders agreed to extend credit to the Company in the form of Term A loans in an aggregate principal amount of $300 million (“Term A Loans”) and a revolving credit facility in an aggregate principal amount of $250 million (“Revolver”).

The amended and restated credit agreement:

• Has an aggregate principal amount of $550 million,
• was used to refinance the Company’s June 29, 2017 Credit Agreement (“2017 Credit Agreement”), which consisted of an aggregate principal amount of $250 million Term A loans and a $250 million revolving credit facility,
• carries substantially the same terms and conditions as the 2017 Credit Agreement,
• includes a $300 million Term A Loan, which replaces the Company’s existing $250 million Term A loan, reflecting a $50 million upsizing of the previous Term A loan facility,
• includes a $250 million Revolver, which replaces the Company’s existing $250 million revolving credit facility,
• extends the maturity of the Company’s credit facilities from June 2022 to April 2026,
• carries an interest rate that is consistent with the Company’s current credit facilities,
• is representative of a widely syndicated group of lenders primarily consisting of the Company’s existing lenders, providing the Company with increased operational flexibility, and
• was jointly arranged by BofA Securities, Inc. and Coöperatieve Rabobank U.A., with Bank of America, N.A. acting as Administrative Agent.